TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12486510
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 0.005% latanoprost and 0.5% timolol once daily in the morning
Study: 12486510
Drug: Latanoprost once
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost once daily in the morning
Study: 18621791
Drug: Timolol twice
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol twice daily
Study: 2979244
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (2 g b.d.)
Study: 28094136
Drug: Usual pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pump therapy
Study: 26351349
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 or 3 mg/kg, intravenous infusion every 2 weeks)
Study: 11185669
Drug: Cholestyramine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (12 g/d) in addition to chronic statin therapy
Study: 9365450
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine 1.9 mg/kg every 12 h plus intravenous placebo (saline)
Study: 9365450
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.04 mg/kg/h plus placebo tablet
Study: 7917912
Drug: BIS‐1 F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐1 F(ab')2 fragments intravenously at doses of 1, 3 and 5 micrograms kg‐1 body weight during s.c. IL‐2 treatment.
Study: 7917912
Drug: BIS‐1 F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms kg‐1.
Study: 7917912
Drug: BIS‐1 F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐1 F(ab')2 treatment.
Study: 23130172
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg daily
Study: 28252882
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) combined with Treatment as Usual (TAU)
Study: 17393260
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylic salicylic acid
Study: 15691900
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation (49.5 g essential amino acids and 90 g carbohydrate per day for 28 days)
Study: 9564116
Drug: Health-care workers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-care workers' evaluation using the Therapy Impact Questionnaire (TIQ)
Study: 2513741
Drug: Flumazenil (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.015 mg/kg IV)
Study: 24285491
Drug: Early metacarpal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early metacarpal bone mineral density (BMD) loss after 4 months of treatment
Study: 23645236
Drug: Ziprasidone (137.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (137.5 mg/d)
Study: 23645236
Drug: Olanzapine (19.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (19.5 mg/d)
Study: 21915616
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum total cholesterol (≥240 mg/dl)
Study: 12605618
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion (RI) of 150 mg thiamine over 1 hour
Study: 12605618
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (SI) of 150 mg thiamine over 24 hours
Study: 9356537
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil treatment (20 g fish oil/d)
Study: 9356537
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil treatment with increased fiber intake (15 g pectin supplement)
Study: 9356537
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil treatment with increased fiber intake
Study: 1607194
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily for 5 days (treated partners)
Study: 3896609
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group I)
Study: 3896609
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (Group II)
Study: 30983049
Drug: Edoxaban for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban for periprocedural oral anticoagulation
Study: 30204689
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg/24 hours)
Study: 27435280
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) followed by surgery
Study: 27435280
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (FLOT protocol)
Study: 18577410
Drug: Diphtheria CRM(197)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria CRM(197)‐based Haemophilus influenzae type b conjugate vaccine (HbOC)
Study: 18577410
Drug: Diphtheria CRM(197)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria CRM(197)‐based combination 9‐valent pneumococcal conjugate vaccine/meningococcal group C conjugate vaccine
Study: 12454841
Drug: Repeated paracentesis
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated paracentesis plus intravenous albumin
Study: 10321658
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, maximum 800 mg, administered intravenously over 30 to 60 mins every 6 hrs for eight doses)
Study: 1722793
Drug: Flutamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (750 mg/day for 6 months)
Study: 7042699
Drug: Amitriptyline, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline, 150 mg/day
Study: 7042699
Drug: Phenelzine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine, 60 mg/day
Study: 17230055
Drug: Physiogel AI
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiogel AI cream
Study: 11248824
Drug: Ofloxacin 0.3%
Normalized name: OFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 0.3% ophthalmic solution
Study: 7517181
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin 75 mg
Study: 31863505
Drug: Xylazine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (0.1 or 0.2 mg/kg)
Study: 31863505
Drug: Acepromazine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acepromazine (0.02 or 0.04 mg/kg)
Study: 31863505
Drug: Local analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local analgesia (4 mL 2% mepivacaine administered subcutaneously)
Study: 31863505
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (1 mL)
Study: 30219460
Drug: Dance Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance Therapy (DT)
Study: 24178750
Drug: IV G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV G‐CSF (5 mcg/kg single daily dose)
Study: 24178750
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF (filgrastim)
Study: 24178750
Drug: IV G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV G‐CSF
Study: 24178750
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF
Study: 24178750
Drug: Both IV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IV and SC G‐CSF
Study: 22864282
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg q.d.)
Study: 22864282
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg b.i.d.)
Study: 19115106
Drug: 2nd-line hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2nd-line hormone therapy
Study: 17661962
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (mailing an antibiotic guide and prescribing profile)
Study: 582985
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg in customary preparation (A 300)
Study: 582985
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg in slow-release preparation (A ret)
Study: 28586888
Drug: Community-based testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based testing and treatment intervention
Study: 19666358
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: Paracetamol suppository at a dose of 15 mg/kg
Study: 19666358
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: Niflumique acid suppository at a dose of 13 mg/kg
Study: 19666358
Drug: Protocol C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C: Combination of paracetamol (15 mg/kg) and niflumique acid (13 mg/kg)
Study: 16170976
Drug: 0.05% cetylpyridinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% cetylpyridinium chloride gel‐releasing interdental brush (IDB)
Study: 7017177
Drug: Oral levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral levodopa and benserazide
Study: 16739327
Drug: Pre-operative IL-2
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative IL-2 immunotherapy (6x10(6) I.U. twice daily for 3 days)
Study: 28104702
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IL-2 treatment)
Study: 16739327
Drug: Pre-operative IL-2
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative IL-2 immunotherapy in Dukes' B patients
Study: 16739327
Drug: Pre-operative IL-2
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative IL-2 immunotherapy in Dukes' C patients
Study: 12387773
Drug: IBS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBS treatment (groups B and D)
Study: 10420108
Drug: Eye gel
Normalized name: EYE GEL
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye gel containing calf blood extract
Study: 10420108
Drug: Eye ointment
Normalized name: EYE OINTMENT
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye ointment containing vitamin A and dexpanthenol
Study: 8585042
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of thromboprophylaxis one week after surgery
Study: 2247864
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg beclomethasone dipropionate via metered dose inhaler alone
Study: 2247864
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg beclomethasone dipropionate via metered dose inhaler with a 750 ml spacing device
Study: 31922512
Drug: Holisal gel
Normalized name: BARRIER,HOLLISEAL H#7708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holisal gel applied 4 times a day in the socket
Study: 17051405
Drug: CEE/MPA (estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (estrogen + 2.5 mg medroxyprogesterone acetate)
Study: 17051405
Drug: E2/NETA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (1 mg 17 beta estradiol + 0.5 mg norethindrone acetate)
Study: 15207399
Drug: E. senticosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. senticosus dry extract 300 mg/day
Study: 11773815
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine with 75 microg of clonidine (Group M)
Study: 11773815
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of bupivacaine with 75 microg of clonidine (Group B)
Study: 9839098
Drug: Strict target
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict target level of glycemic control (fasting capillary glucose < 6.5 mmol/l)
Study: 9839098
Drug: Less strict
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less strict target level of glycemic control (fasting capillary glucose < 8.5 mmol/l)
Study: 8076623
Drug: 2-chloropropionate (2-CP)
Normalized name: CHLOROPROPYLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-chloropropionate (2-CP) 43 mg.kg-1 body mass
Study: 2634922
Drug: 0.5 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg. of PGE2 in 2 ml of tylose gel intracervically (group A)
Study: 2634922
Drug: 3.0 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg. of PGE2 in 5 ml of tylose gel intravaginally (group B)
Study: 16150200
Drug: Xuesaitong soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong soft capsule (XST), 2 capsules orally, twice a day for 8 weeks.
Study: 16150200
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicines (mannitol, troxerutin, citicoline, piracetam, aspirin)
Study: 10367822
Drug: Oral methionine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine, 100 mg/kg in fruit juice
Study: 10367822
Drug: Oral methionine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine, 100 mg/kg in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Study: 8554933
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg orally in CF patients
Study: 8554933
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg orally in healthy controls
Study: 2047051
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound management protocol without aloe vera gel
Study: 6117537
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg clobazam
Study: 24952577
Drug: Standard PCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PCV chemotherapy (procarbazine, CCNU, and vincristine)
Study: 24952577
Drug: Standard temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard temozolomide (TMZ) 5-day schedule (200 mg/m2/day)
Study: 24952577
Drug: Standard temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard temozolomide (TMZ) 21-day schedule (100 mg/m2/day)
Study: 19196930
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (14 infusions)
Study: 11841402
Drug: G‐CSF (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim) administered from 48 hours after completing chemotherapy until absolute neutrophil count exceeded 1.5 x 10(9)/l
Study: 11841402
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G‐CSF unless severe infection occurred)
Study: 10735895
Drug: Temozolomide (TEM)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TEM) 200 mg/m²/d orally for 5 days every 28 days
Study: 10735895
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) 250 mg/m²/d IV for 5 days every 21 days
Study: 9176076
Drug: Short chain
Normalized name: Short chain acyl-CoA dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks
Study: 9176076
Drug: Short chain
Normalized name: Short chain acyl-CoA dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks in patients with a short episode of colitis (< 6 months)
Study: 9176076
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in patients with a short episode of colitis (< 6 months)
Study: 9176076
Drug: Open-label SCFA
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label SCFA treatment after the controlled trial
Study: 1414149
Drug: thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: thymopentin (50 mg)
Study: 3551894
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g in a single oral dose)
Study: 29563633
Drug: Antidiabetic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drug use
Study: 27066804
Drug: Patient-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-driven titration tools for mealtime insulin
Study: 12632354
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia (0.25% bupivicaine, 1 mL/kg)
Study: 8973788
Drug: Manidipine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 40 mg
Study: 28934781
Drug: Lateral decubitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral decubitus position (Group L)
Study: 24107763
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for PTSD, 8 once-weekly sessions
Study: 21317177
Drug: PF-00547,659 (0.03-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547,659 (0.03-10 mg/kg IV/SC, single or multiple doses at 4-week intervals)
Study: 15801579
Drug: No Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Spray
Study: 17894080
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 5 mg
Study: 17894080
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 2 mg
Study: 17894080
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 1 mg
Study: 28839339
Drug: Valbenazine (VBZ)
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valbenazine (VBZ) 1, 2, 5, or 12.5 mg (Cohort 1) and 12.5, 25, 50, or 75 mg (Cohort 2) single doses
Study: 28839339
Drug: Valbenazine (VBZ)
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valbenazine (VBZ) 75, 100, 125 or 150 mg single doses
Study: 28839339
Drug: Valbenazine (VBZ)
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valbenazine (VBZ) 50 or 100 mg once-daily for 8 days (Cohort 1)
Study: 28839339
Drug: Valbenazine (VBZ)
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valbenazine (VBZ) 50 mg once-daily for 8 days (Cohort 2)
Study: 23876867
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (3 monthly injections)
Study: 15488870
Drug: Atorvastatin 10mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10mg/day (A)
Study: 15488870
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + Atorvastatin (E + A)
Study: 11673867
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of o,o'-[(14)C]dityrosine into mice
Study: 7884017
Drug: Intramuscular zuclopenthixol
Normalized name: zuclopenthixol
DrugBank: Zuclopenthixol (DB01624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular zuclopenthixol acetate (50 to 150 mg every 3 days)
Study: 7884017
Drug: Liquid oral
Normalized name: M-End Liquid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral haloperidol (10 to 30 mg daily, three times a day)
Study: 31843270
Drug: Strep A
Normalized name: Sofia Strep A+ FIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strep A vaccine (StreptAnova™), administered intramuscularly at 0, 30, and 180 days
Study: 31843270
Drug: Strep A
Normalized name: Sofia Strep A+ FIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strep A vaccine (StreptAnova™)
Study: 21279976
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline
Study: 21279976
Drug: Pulse steroid
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse steroid and cyclophosphamide therapy
Study: 10436756
Drug: SonoVue 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 0.3 ml
Study: 10436756
Drug: SonoVue 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 0.6 ml
Study: 10436756
Drug: SonoVue 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 1.2 ml
Study: 16421404
Drug: SonoVue 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 2.4 ml
Study: 7372822
Drug: Hypnotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic treatment
Study: 7372822
Drug: Trophotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophotropic treatment
Study: 31216846
Drug: PIEB 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB 10 ml every 60 min (Group 10q60)
Study: 31216846
Drug: PIEB 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB 5 ml every 30 min (Group 5q30)
Study: 31216846
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) 10 ml/h
Study: 26088268
Drug: Idarucizumab 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab 1 g
Study: 26088268
Drug: Idarucizumab 2
Normalized name: idaruCIZUmab 2.5 GM in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab 2 g
Study: 26088268
Drug: Idarucizumab 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab 4 g
Study: 26088268
Drug: Idarucizumab 5
Normalized name: idaruCIZUmab 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab 5 g plus 2.5 g